PRAM1 Antikörper (AA 551-650)

Produktnummer ABIN1713884

Der Kaninchen Polyklonal Anti-PRAM1-Antikörper wurde für ELISA, IF (cc), IF (p), IHC (p), IHC (fro) und ICC validiert. Er ist geeignet, PRAM1 in Proben von Human zu detektieren.

Kurzübersicht für PRAM1 Antikörper (AA 551-650) (ABIN1713884)

Target: PRAM1 (PML-RARA Regulated Adaptor Molecule 1 (PRAM1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PRAM1 Antikörper ist unkonjugiert

Applikation: ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunocytochemistry (ICC)

Produktdetails anti-PRAM1 Antikörper

Bindungsspezifität: AA 551-650

Kreuzreaktivität: Human

Homologie: Mouse,Rat,Dog,Cow,Sheep,Pig,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human PRAM1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu PRAM1

Target: PRAM1 (PML-RARA Regulated Adaptor Molecule 1 (PRAM1))

Andere Bezeichnung: PRAM1

Hintergrund:

Synonyms: PML RAR, PML RARA regulated adaptor molecule 1, PML RARA target gene encoding an Adaptor Molecule 1, PML-RARA-regulated adapter molecule 1, PRAM 1, PRAM, PRAM-1, PRAM_HUMAN, PRAM1.

Background: Complete remission of acute promyelocytic leukemia can be achieved by treating patients with retinoic acid, and PML-RAR-a (promyelocytic leukemia-retinoic acid receptor alpha fusion protein) plays a major role in mediating retinoic acid effects in leukemia cells. The retinoic acid-induced gene, PRAM-1 (PML-RAR-a target gene encoding an adaptor molecule 1) encodes an adaptor protein which is expressed and modulated during normal human myelopoiesis. PRAM-1 expression is hindered by expression of PML-RAR-a. The 718 amino acid PRAM-1 protein contains eight N-terminal proline-rich repeats and several proline residues that are clustered as type I or type II SH3 recognition motifs. PRAM-1 demonstrates expression in hematopoietic tissues and lung.

Pathways: Regulation of Leukocyte Mediated Immunity